Skip to main content
Supplement Research and Comparison WebsiteBest Price GuaranteeAbout Us
Supplement Research and Comparison Website

Effect of bifidobacterium breve A-1 on anxiety and depressive symptoms in schizophrenia: A proof-of-concept study.

  • 2019-02
  • Journal of Affective Disorders 245
    • R. Okubo
    • Minori Koga
    • N. Katsumata
    • T. Odamaki
    • Shiina Matsuyama
    • Matsuhiko Oka
    • H. Narita
    • N. Hashimoto
    • I. Kusumi
    • Jinzhong Xiao
    • Y. Matsuoka

Abstract

Background: Studies of probiotics have suggested they have a positive effect on anxiety and depressive symptoms in humans. This study investigated the effect of consuming the probiotic Bifidobacterium breve A-1 on anxiety and depressive symptoms in patients with schizophrenia and explored its effect on immune products such as cytokines and chemokines.

Methods: In this open-label single-arm study, all participants received B. breve strain A-1 (1011 cfu/day) for 4 weeks followed by 4 weeks of observation. The primary outcome was the Hospital Anxiety and Depression Scale (HADS) score. Secondary outcomes were anxiety and depressive symptoms on the Positive and Negative Syndrome Scale (PANSS), blood test findings, and fecal microbiome composition.

Results: Twenty-nine outpatients completed the study. HADS total score and PANSS anxiety/depression score were significantly improved at 4 weeks. Based on the criterion of a greater than 25% reduction in HADS total score at 4 weeks from baseline, there were 12 responders and 17 non-responders. Responders were found to have fewer negative symptoms, reduced intake of dairy products, and higher relative abundance of Parabacteroides in the gut microbiome than non-responders. Moreover, IL-22 and TRANCE expression was significantly increased at 4 weeks from baseline in responders but not in non-responders.

Limitations: This open-label, single-arm study cannot exclude a placebo effect.

Conclusions: The results suggest the potential effect of B. breve A-1 in improving anxiety and depressive symptoms in patients with schizophrenia. Further studies should investigate this effect in patients with other psychiatric conditions and assess dietary habits and the gut microbiome.

Keywords: Anxiety; Cytokines; Depression; Microbiome; Probiotics; Schizophrenia.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium breveAltered Gut Microbiota CompositionBeneficial
Small
Bifidobacterium breveImproved Anxiety SymptomsBeneficial
Moderate
Bifidobacterium breveImproved Depressive SymptomsBeneficial
Moderate
Bifidobacterium breve Bb-03Reduced Anxiety SymptomsBeneficial
Moderate
Bifidobacterium breve Bb-03Reduced Depression SymptomsBeneficial
Moderate
Bifidobacterium breve BBr60Increased Interleukin-22 ExpressionBeneficial
Moderate
Bifidobacterium breve BBr60Increased TRANCE ExpressionBeneficial
Moderate
Bifidobacterium breve Bbr8Improved Anxiety SymptomsBeneficial
Moderate
Bifidobacterium breve Bbr8Improved Depressive SymptomsBeneficial
Moderate
Bifidobacterium breve BR-03Modulated Immune ResponseBeneficial
Moderate
Bifidobacterium breve HA-129Reduced Anxiety LevelsBeneficial
Moderate
Bifidobacterium breve HA-129Reduced Depression SymptomsBeneficial
Moderate
Bifidobacterium breve M-16VAltered Expression of Immune ProductsNeutral
Moderate
Bifidobacterium breve M-16VImproved Anxiety SymptomsBeneficial
Moderate
Bifidobacterium breve M-16VImproved Depressive SymptomsBeneficial
Moderate
Bifidobacterium breve R0070Improved Anxiety SymptomsBeneficial
Moderate
Bifidobacterium breve R0070Improved Depressive SymptomsBeneficial
Moderate
Bifidobacterium breve SD5206Improved Anxiety SymptomsBeneficial
Moderate
Bifidobacterium breve SD5206Improved Depressive SymptomsBeneficial
Moderate
Bifidobacterium breve UABbr-11Increased Interleukin-22 ExpressionBeneficial
Moderate
Bifidobacterium breve UABbr-11Increased TRANCE ExpressionBeneficial
Moderate
Bifidobacterium breve UABbr-11Reduced Anxiety SymptomsBeneficial
Moderate
Bifidobacterium breve UABbr-11Reduced Depression SymptomsBeneficial
Moderate
Bifidobacterium breve VPro 52Enhanced Immune ResponseBeneficial
Moderate
⬆ Back to top
Unsubscribe anytime. See our Privacy Policy.
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.

Join Our Community

Statements on this website have not been reviewed by the U.S. Food and Drug Administration. These products are not meant to diagnose, treat, cure, or prevent any disease. The information here is not a replacement for personal medical advice.